Find a Physician | How to Contribute | About Us | Clinical Trials
Search: 
Select a Cancer Type:
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Clinical Trial DRUG STML-701-0114

Title
A Phase 1/2 Study of SL-701, a Subcutaneously Injected Multivalent Glioma-Associated Antigen Vaccine, in Adult Patients with Recurrent Glioblastoma Multiforme
Principal Investigator
Priya Kumthekar
Details
  • Status: Accepting New Patients
  • Study Type: Therapeutic, Treatment
  • Protocol No:.DRUG STML-701-0114
Purpose
The goal of this research study is to establish the safety and tolerability of the drug SL-701, and to determine its effects on patients with recurrent Glioblastoma Multiforme (GBM) tumors.
Overview
SL-701 is an experimental medication. This means that the United States Food and Drug Administration (FDA) has not yet approved SL-701. SL-701 is an anti-cancer immunotherapy that uses 3 different short proteins, called “peptides,” that are found in certain brain tumors. The immunotherapy is designed to activate the immune system to recognize and kill brain-tumor cells that display proteins similar to the peptides in SL-701.
Eligibility
Some of the eligibility criteria include:
  • Participants must be 18 years of age or older.
  • Participants must have tumor recurrence (cancer came back) or progression (cancer is worsening)after initial (first) treatment.
  • Participants who received prior cancer chemotherapy with bevacizumab or other VEGF-VEGFR-directed agents (check with the study doctor for any exclusions) cannot participate in this study.
Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Description of Treatment
Participants will receive SL-701 as an injection (shot by needle) along with an additional medication that will make the immune response stronger. This additional medication (poly-ICLC) is referred to as an adjuvant. Participants will also receive bevacizumab (approved by the FDA for the treatment of GBM) in combination with SL-701 and poly-ICLC. To receive study treatment, participants will come to the study center two times per week for the first 2 weeks, every week for the next 2 weeks, and every 2 weeks thereafter through Week 22. After Week 22, participants will come to the clinic every 4 weeks to receive SL-701 and poly-ICLC injections. Bevacizumab will continue to be given every 2 weeks after Week 22.
Contact
Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
312.695.1102
cancertrials@northwestern.edu

Find Related Clinical Trials

Browse by Disease Sites

Other Clinical Trials by Priya Kumthekar

last updated: 02-Jul-16 02:34 AM

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.